Canadian company invests in Taiwanese biotechnology:
This article was originally published in Clinica
Executive Summary
The Taiwanese government has entrusted $30 million of its biotechnology development fund to MDS Capital, a Canadian venture capital firm, to invest in various industry sectors, including biomedical devices, drug delivery systems and diagnostics. The move follows a recent $580 million boost from the government to help its biotech industry increase its value to $880 million by 2005 (see Clinica No 820, p 2). The company is expected to help complete ten technology transfer projects in Taiwan within the next five years.